Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Circulating biomarkers for high-grade glioma.

Loo HK, Mathen P, Lee J, Camphausen K.

Biomark Med. 2019 Feb;13(3):161-165. doi: 10.2217/bmm-2018-0463. Epub 2019 Feb 26. No abstract available.

2.

miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients.

Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y, Hua W, Yang I, Fu CC, Nolan J, Nakano I, Yang Y, Beaulieu M, Carter BS, Chen CC.

J Neurooncol. 2015 Jun;123(2):205-16. doi: 10.1007/s11060-015-1784-3. Epub 2015 Apr 23.

3.

Detection of glioblastoma in biofluids.

Figueroa JM, Carter BS.

J Neurosurg. 2018 Aug;129(2):334-340. doi: 10.3171/2017.3.JNS162280. Epub 2017 Oct 20.

PMID:
29053069
4.

A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.

Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V, Carapella C, Piaggio G, Pelosi A, Rizzo MG.

J Exp Clin Cancer Res. 2016 Jul 30;35(1):124. doi: 10.1186/s13046-016-0393-0.

5.

Circulating microRNA biomarkers for glioma and predicting response to therapy.

Tumilson CA, Lea RW, Alder JE, Shaw L.

Mol Neurobiol. 2014 Oct;50(2):545-58. doi: 10.1007/s12035-014-8679-8. Epub 2014 Apr 3. Review.

PMID:
24696266
6.

Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.

Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J.

J Neurosurg. 2016 Jan;124(1):122-8. doi: 10.3171/2015.1.JNS141577. Epub 2015 Jul 31.

PMID:
26230475
7.

Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis.

Ebrahimkhani S, Vafaee F, Hallal S, Wei H, Lee MYT, Young PE, Satgunaseelan L, Beadnall H, Barnett MH, Shivalingam B, Suter CM, Buckland ME, Kaufman KL.

NPJ Precis Oncol. 2018 Dec 12;2:28. doi: 10.1038/s41698-018-0071-0. eCollection 2018.

8.

Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.

Siegal T, Charbit H, Paldor I, Zelikovitch B, Canello T, Benis A, Wong ML, Morokoff AP, Kaye AH, Lavon I.

J Neurosurg. 2016 Oct;125(4):1008-1015. Epub 2016 Jan 22.

PMID:
26799295
9.

MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development.

Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC.

PLoS One. 2013 Oct 21;8(10):e78115. doi: 10.1371/journal.pone.0078115. eCollection 2013.

10.

A cerebrospinal fluid microRNA signature as biomarker for glioblastoma.

Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, Quan K, Zhu W, Li J, Figueroa J, Hirshman BR, Miller B, Piccioni D, Ringel F, Komotar R, Messer K, Galasko DR, Hochberg F, Mao Y, Carter BS, Chen CC.

Oncotarget. 2017 Jun 1;8(40):68769-68779. doi: 10.18632/oncotarget.18332. eCollection 2017 Sep 15.

11.

Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients.

Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, Zhang CG, Jiang T, Li WB, Ding W, Cheng SJ.

Oncotarget. 2015 Sep 29;6(29):26971-81. doi: 10.18632/oncotarget.4699.

12.

Liquid biopsies in patients with diffuse glioma.

Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T.

Acta Neuropathol. 2015 Jun;129(6):849-65. doi: 10.1007/s00401-015-1399-y. Epub 2015 Feb 27.

13.

Extracellular Vesicles from Neurosurgical Aspirates Identifies Chaperonin Containing TCP1 Subunit 6A as a Potential Glioblastoma Biomarker with Prognostic Significance.

Hallal S, Russell BP, Wei H, Lee MYT, Toon CW, Sy J, Shivalingam B, Buckland ME, Kaufman KL.

Proteomics. 2019 Jan;19(1-2):e1800157. doi: 10.1002/pmic.201800157.

PMID:
30451371
14.

Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.

Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, Ringel F, Yang I, Kalkanis S, Thompson R, LoGuidice L, Berghoff E, Parsa A, Liau L, Curry W, Cahill D, Bettegowda C, Lang FF, Chiocca EA, Henson J, Kim R, Breakefield X, Chen C, Messer K, Hochberg F, Carter BS.

Neuro Oncol. 2017 Oct 19;19(11):1494-1502. doi: 10.1093/neuonc/nox085.

15.

MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma.

Wang Z, Jiang W, Wang Y, Guo Y, Cong Z, DU F, Song B.

Biomed Rep. 2015 Jul;3(4):543-548. Epub 2015 May 13.

16.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

17.

Comprehensive analysis of microRNA expression profile in malignant glioma tissues.

Piwecka M, Rolle K, Belter A, Barciszewska AM, Żywicki M, Michalak M, Nowak S, Naskręt-Barciszewska MZ, Barciszewski J.

Mol Oncol. 2015 Aug;9(7):1324-40. doi: 10.1016/j.molonc.2015.03.007. Epub 2015 Mar 25.

18.

Centrifugation affects the purity of liquid biopsy-based tumor biomarkers.

Rikkert LG, van der Pol E, van Leeuwen TG, Nieuwland R, Coumans FAW.

Cytometry A. 2018 Dec;93(12):1207-1212. doi: 10.1002/cyto.a.23641.

PMID:
30551256
19.

Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers?

Erdbrügger U, Le TH.

J Am Soc Nephrol. 2016 Jan;27(1):12-26. doi: 10.1681/ASN.2015010074. Epub 2015 Aug 6. Review.

20.

The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.

Hallal S, Ebrahimkhani S, Shivalingam B, Graeber MB, Kaufman KL, Buckland ME.

Brain Tumor Pathol. 2019 Mar 11. doi: 10.1007/s10014-019-00335-0. [Epub ahead of print] Review.

PMID:
30859343

Supplemental Content

Support Center